Papers and patents that deal with polymorphism (crystal systems for which a substance can
exist in structures defined by different unit cells and where each of the forms has the same …

Abstract Carvedilol ((2RS)-1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy) ethyl] amino]
propan-2-ol), a β1-, β2-, and α1-adrenoreceptor blocker drug with antioxidant and …

Carvedilol (Table I) is a non-selective β-blocker indicated in the treatment of mild to
moderate congestive heart failure. It also has vasodilating properties that are mainly …

Coamorphous drug formulations are a promising approach to improve solubility and
bioavailability of poorly water-soluble drugs. On the basis of theoretical assumptions …

Five pharmaceutically relevant compounds with increasing molecular complexity, benzoic
acid, diphenylacetic acid, l-tyrosine, celecoxib (form III), and carvedilol (form II), were …

Carvedilol (CVD) is a β-blocker antihypertensive drug commonly used to treat
cardiovascular disorders. Since the poor oral bioavailability of CVD can be improved directly …

Carvedilol, a β-blocker drug used to treat hypertension, is known to exhibit polymorphism.
Thus far, the crystal structure of two polymorphs (I and II) and one hydrate have been …

Crystallisations on both the academic and industrial scale often use large volumes of
solvent. In order to decrease the environmental impact of such processes, new techniques …

The thermal behaviour of crystalline and amorphous carvedilol (CAR) phases was studied
by advanced thermal analysis using Quantum Design Physical Property Measurement …

The thermal behavior of carvedilol and loratadine was studied by differential scanning
calorimetry (DSC). The glass-forming ability, as well as the the tendency for crystallization …